BCHE and Alzheimer disease: Presently, pharmacological interventions of cholinergic and glutamatergic neurotransmission, including cholinesterase inhibitors and N-Methyl-D-Aspartate (NMDA) receptors antagonist, are the only FDA-approved medications for AD but are unable to significantly improve cognitive dysfunction [210].